Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systolic dysfunction. A 6 to 12-month randomised double blind parallel groups multicentre study.
Phase of Trial: Phase III
Latest Information Update: 19 Sep 2014
At a glance
- Drugs Ivabradine (Primary)
- Indications Chronic heart failure; Left ventricular dysfunction
- Focus Adverse reactions
- 28 Nov 2012 New trial record